← back to database
Ascenta Capital makes concentrated $15M–$30M investments in development-stage biotechnology companies translating preclinical science into early human data. It focuses on multi-medicine platforms and works closely with management teams on clinical, regulatory, manufacturing and capital strategy.
Check size
Specialization
Generalist / Specialist
Specialist
Latest fund size
$325M Inaugural Fund
Latest fund vintage
2025
Investing team
Evan RachlinCo-Founder and Managing Partner
John GutierrezPrincipal
Leighanne OhVice President